[TREATMENT AND PREVENTION OF COMBINED CARDIO-RESPIRATORY PATHOLOGY IN EXACERBATION OF CHRONIC OBSTRUCTIVE-PULMONARY DISEASE (new approach)].

The features of the course of exacerbations of chronic obstructive pulmonary disease (COPD) in combination with coronary heart disease in the form of stable angina, and with the threat of destabilizing its course. The changes of the cardiovascular system in patients with a background of clinical symptoms in patients with acute exacerbation of COPD II-III stages. A differentiated approaches to anti-inflammatory and cardio protective action of drug combinations Roflumilast and quercetin as components of adjuvant therapy in patients with combined cardiovascular disease.

[Proinflammatory cytokines and C-reactive protein in urine: prospects for diagnosis in patients with chronic pyelonephritis].

The study involved 85 patients with chronic pyelonephritis in age from 26 to 62 years. All patients determined C-reactive protein (CRP), interleukin 6 and tumor necrosis factor-alpha in the blood and urine by standard techniques. With the simultaneous study of CRP in the blood and urine of patients with chronic pyelonephritis detected high levels of this biomarker in the urine, which is several times higher than its indicators levels in blood. When studying the levels of proinflammatory cytokines, which are the main inducers excretion of CRP, we found that the increase in their concentration in urine was more pronounced than in the blood, which confirms the opinion that CRP can be synthesized in inflammation focus by lymphocytes, macrophages and endothelial. Studying the levels of cytokines and C-reactive protein in the urine can be used to assess the severity of inflammatory changes in the kidney and to monitor the effectiveness of anti-inflammatory therapy.

[Role of interleukin-1 and interleukin-2 in the pathogenesis of systemic scleroderma]. / Interleikin-1 ta interleikin-2 u patohenezi systemnoï sklerodermiï.

The purpose of a research was to define the levels of interleukin-1 (IL-1) and interleukin-2 (IL-2) in patients with systemic scleroderma (SSc) and to analyse their dependence on the course of the illness. 75 patients with SSc and 20 apparently healthy people were examined. Besides the well-known clinical-biochemical and instrumental investigations, the levels of IL-1 and Il-2 in all the patients were determined in serum with an immunoenzymatic method using a set of reactants Pro Con IL-1b and Pro Con IL-2 (Russia). The data obtained give evidence for an increase in both IL-1 and IL-2 levels. As the correlation between the level of IL-1 and the acuteness of the pathological process has been shown to be especially distinct, it can be used for marking an acute form of this pathology. Thus, both parametres (IL-1, IL-2) depend on the acuity and peculiarities of SSc, and on the concomitant damage of the internal organs. The most pronounced increase in LL-2 level has been observed at visceralisation of SSc.

[Use of pentoxifylline in the treatment of systemic scleroderma]. / Zastosuvannia pentoksyfilinu v likuvanni systemnoï sklerodermiï.

Analyzes in the paper are chief pharmacological effects of pentoxifylline; the necessity is substantiated of its prescription in a combined therapy of systemic scleroderma (SSD). As many as 220 SSD patients on an in-patient care were examined. Apart from general clinical, biochemical, immunological methods of investigation, the condition of the microcirculation system was studied, the level of the tumor necrosis serumal factor alfa (TNF-alpha) was measured. The data secured suggest a considerable increase in the level of TNF-alpha and pronounced disturbances in microcirculation. The administration of pentoxifylline to SSD patients has been found to improve the microcirculation and reduce the production of the above factor, which fact suggests its immunomodulating properties.

[Osteocalcin--a marker of bone metabolism in rheumatoid arthritis patients]. / Osteokal'tsyn--marker kistkovoho metabolizmu u khvorykh na revmatoïdnyi artryt.

Blood serum concentration of osteocalcin was studied in 53 patients with rheumatoid arthritis. Osteocalcin (noncollagenous protein of bony tissue) is a marker of bony tissue formation known to be of high informative value. There were no significant differences in values for osteocalcin concentration between patients with rheumatoid arthritis and healthy people. Reduction of osteocalcin content and, correspondingly, of process of bony tissue formation was observed in rapidly progressing course of rheumatoid arthritis and in stage IV arthritis. Rises in osteocalcin concentration were recordable in those women in there postmenopause. Patients with rheumatoid arthritis were found out to experience adequate formation of bony tissue in spite of the osteopenia syndrome progression. Disordered structural and functional state of the bony tissue processes of remodelling may be explained by bony tissue remodeling processes dissociation.

[A new approach to the treatment of patients with circulatory encephalopathy]. / Novyi pidkhid do likuvannia khvorykh na dystsyrkuliatornu entsefalopatiiu.

Effects were studied of vincamin and tanakan in 68 patients with stage I, II and III discirculatory encephalopathy (as per WHO classification 1981). In 52% of the patients atherosclerosis of brain vessels was associated with arterial hypertension (group I), in 48 per cent venous discirculatory encephalopathy was diagnosable against the background of arterial hypertension (group IIA-20%) and arterial hypotension (group IIB-26%). Both tanakan and vincamin were found to be effective in group I patients; however, in stage III condition their effectiveness was no better than 42 and 15% respectively, which fact might be due to organic changes in the vascular wall. Tanakan appeared to be more beneficial in group II patients since venous dystonia is considered to be the main pathogenetic link in this context, and tanakan is known to improve the venous outflow from the cranial cavity. Almost in one-third of group IIB patients vincamin worsened general health status, especially so in stage III discirculatory encephalopathy, which fact may be related to peculiar effect of the drug on the arterial link of brain blood supply.

[The effect of etimizol on the glycosaminoglycan level in patients with osteoarthrosis deformans]. / Vplyv etymizolu na riven' hlikozaminohlikaniv u khvorykh na deformuiuchyi osteoartroz.

Aetymizolum was studied for its efficacy in the treatment of patients with osteoarthrosis. The results obtained suggest that aethymizolum is capable of correcting the levels of glycosaminoglucans in the patients' blood serum. With the content of the latter being dependent upon the degree of the articular cartilage destruction in osteoarthrosis deformans, it is suggested that aethymizolum while being endowed with reparative and membrane stabilizing properties may at the same time influence the articular cartilage metabolism and decrease the intensity of the destruction of the later. Effect of aethymizolum is more pronounced in mono-oligoarthrosis and polyosteoarthrosis as well as in stages II and III of the disease course. Conventional therapies (indomethacin, humisolum, Fibs, physiotherapeutic procedures, remedial gymnastics, massage) have no effect on these parameters.